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Abstract
Background: Spain was the country that registered the greatest increases in ovarian cancer
mortality in Europe. This study describes the municipal distribution of ovarian cancer mortality in
Spain using spatial models for small-area analysis.
Methods: Smoothed relative risks of ovarian cancer mortality were obtained, using the Besag,
York and Molliè autoregressive spatial model. Standardised mortality ratios, smoothed relative
risks, and distribution of the posterior probability of relative risks being greater than 1 were
depicted on municipal maps.
Results: During the study period (1989–1998), 13,869 ovarian cancer deaths were registered in
2,718 Spanish towns, accounting for 4% of all cancer-related deaths among women. The highest
relative risks were mainly concentrated in three areas, i.e., the interior of Barcelona and Gerona
(north-east Spain), the north of Lugo and Asturias (north-west Spain) and along the Seville-Huelva
boundary (in the south-west). Eivissa (Balearic Islands) and El Hierro (Canary Islands) also
registered increased risks.
Conclusion: Well established ovarian cancer risk factors might not contribute significantly to the
municipal distribution of ovarian cancer mortality. Environmental and occupational exposures
possibly linked to this pattern and prevalent in specific regions, are discussed in this paper. Small-
area geographical studies are effective instruments for detecting risk areas that may otherwise
remain concealed on a more reduced scale.
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Background
In 2002, ovarian cancer was the sixth leading tumour and
the seventh leading cause of cancer-related death in
women world-wide [1]. In Spain, a total of 1760 ovarian
cancer deaths were registered in 2006, accounting for
4.6% of all cancer-related deaths in women [2]. Insofar as
incidence is concerned, is highest in developed countries.
Within Europe, the lowest rates correspond to Mediterra-
nean countries whereas the highest are found in Northern
Europe. In 2002, the Spanish incidence rate, adjusted for
the standard world population, was estimated at 9.9 cases
per 100,000 person-years [3]. However, data of cancer
incidence obtained from the provincial registers available
in Spain differ from 11 cases per 100,000 person-years in
Asturias (in the period 1996–2000) to 6 cases in Albacete
(in the period 1998–2001) [4]. In terms of trend, Spain
witnessed an increase of 2% p.a. in this tumour's inci-
dence from the late 1980s to the late 1990s [5]. On the
other hand, Spain along with Greece, is the country to
have recorded the greatest increases in mortality due to
this tumour in Europe [6]. Analysis of the components of
this trend reveals a notably strong and sustained increase
in birth-cohort-related risk until the 1930s, with the slope
levelling off thereafter. A moderate period effect is also in
evidence, with risk rising from 1972–1976 onwards [7].
In Spain, survival from this tumour in the period 1990–
1994 ranked among the highest in Europe, with a cumu-
lative survival of 43% at 5 years. This 5-year survival is
substantially lower for females aged 75 and over (25%)
compared with younger females (73% 15–44 years) [8],
and it has not changed in a ten year period showing a rate
of 35.8% in 1990–94 and a rate of 36.5% in 1995–99 [9].
Well-confirmed risk factors for ovarian cancer are age (the
tumour being rare in women under 40 years, with the risk
increasing sharply thereafter), family history of ovarian
cancer, BRCA carrier status and endometriosis, whereas
increasing parity, oral contraceptive use, and tubal liga-
tion are inversely associated with risk. There is also a prob-
able increase in risk with postmenopausal hormone
therapy, ionising radiation, asbestos exposures and talc
use, and a decrease in risk with lactation and hysterectomy
[10-12]. There are a number of hypotheses as to the aeti-
ology of ovarian cancer. Of these, the most cited is the
incessant ovulation hypothesis [13], which states that
long duration of ovulatory menstrual cycles increases the
risk of developing ovarian cancer. However, there are
other alternative theories to explain the pathogenesis of
this tumour, such as the inflammation hypothesis [14],
the retrograde transport hypothesis [15] and several hor-
monal theories, including the gonadotropin, androgen,
progesterone, oestrogen, insulin-like growth factor-I and
insulin hypotheses [16].
One of the classic approaches in epidemiology is the study
of geographical distribution. In administrative terms,
Spain is divided into Autonomous Regions known as
Comunidades Autónomas. These are in turn subdivided into
provinces and, at the lowest level, into municipalities.
Ovarian cancer mortality has been previously studied at a
provincial level and has been shown to be more pro-
nounced in the provinces of Asturias, Seville and Barce-
lona [17]. Small-area analysis allows for a greater level of
disaggregation, thereby improving interpretation of
results and detection of local effects that might be linked
to specific geographic, social or environmental character-
istics, while at the same time reducing ecological biases
[18]. This study set out: to analyse the spatial distribution
of ovarian cancer mortality at a municipal level in Spain,
with the aim of highlighting interregional or municipal
patterns; and to discuss the possible relationship between
such distribution and the risk factors outlined above.
Methods
Individual entries for the period 1989–1998, correspond-
ing to deaths in towns and cities throughout Spain due to
ovarian cancer (International Classification of Diseases,
ICD-9 code 183), were used as the case source. These data
were supplied by the National Statistics Institute (Instituto
Nacional de Estadística) for the production of a municipal
cancer mortality atlas.
Municipal populations, broken down by age group (18
groups) and sex, were drawn from the 1991 census and
1996 municipal voters roll. These years correspond to the
midway points of the two quinquennia comprising the
study period (1989–1993 and 1994–1998). The person-
years for each five-year period were estimated by multiply-
ing these populations by 5.
Standardised mortality ratios (SMRs) were obtained as the
ratio between observed and expected deaths. For the cal-
culation of expected cases, the overall Spanish mortality
rates for the above two 5-year periods were applied to
each town's person-years by age group, sex and quinquen-
nium.
To draw up these maps, smoothed municipal relative risks
(RRs) were calculated using the autoregressive conditional
model proposed by Besag, York and Molliè. This model
was introduced by Clayton and Kaldor [19], developed by
Besag, York and Molliè [20], and subsequently applied in
the field of ecological studies [21]. Such models are based
on fitting spatial Poisson models with two random-effect
terms that take the following into account: a) the effects
which vary in a structured manner in space (municipal
contiguity); and, b) a component that models the effects
which vary among municipalities in an unstructured man-BMC Cancer 2008, 8:258 http://www.biomedcentral.com/1471-2407/8/258
Page 3 of 10
(page number not for citation purposes)
ner (municipal heterogeneity) [22]. The model takes the
following form
where: λi is the relative risk in area i; Oi is the number of
deaths in area i; α is the intercept; Ei are the expected
number of cases; hi is the municipal heterogeneity term;
and bi is the spatial term.
The models were fitted using Bayesian Markov chain
Monte Carlo simulation methods with improper priors
[23]. Posterior distributions of RRs were obtained using
WinBugs [24]. The criterion of contiguity needed for the
model was adjacency of municipal boundaries. Conver-
gence of the simulations was verified using the BOA
(Bayesian Output Analysis) R programme library [25].
Given the great number of parameters of the models, the
convergence analysis was performed on a randomly
selected sample of 10 towns and cities, taking 4 strata
defined by municipal size. Convergence of the estimators
was achieved before 100,000 iterations. In the present
study, a "burn-in" (iterations discarded to ensure conver-
gence) of 300,000 iterations was performed, and the pos-
terior distribution was derived using 5,000 iterations. The
CPU time on a Pentium 2 GHz was 18 hours.
A Geographic Information System (GIS) was used to cre-
ate municipal maps of SMRs, smoothed RR estimates, and
the posterior probability that RR > 1. In the case of this
last-mentioned indicator, we applied Richardson's crite-
rion [18], which recommends that probabilities over 0.8
be deemed significant.
Results
From 1989 to 1998, a total of 13,869 deaths due to ovar-
ian cancer were registered in 2,718 Spanish towns. In
comparative terms, this tumour caused 4% of cancer
deaths, which amounted to 0.8% of all female deaths in
this period.
To give an overall picture, Figure 1 shows ovarian cancer
mortality by province. The province with highest mortal-
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Provincial distribution of ovarian cancer mortality Figure 1
Provincial distribution of ovarian cancer mortality. Spain, 1989–1998.
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ity was Asturias (SMR = 1.17), followed by Barcelona, Val-
ladolid, Guadalajara, Seville and Gerona. Navarre, in
contrast, was the province with lowest mortality (SMR =
0.60).
Figure 2 depicts the SMR distribution pattern. This map
shows the polarisation of the distribution towards its
extremes (towns with and without cases), with no specific
pattern being clearly discernable. The "noise" present in
this map, deriving from the instability of the indicator,
was eliminated by means of the smoothing procedure.
From the smoothed map (Figure 3), three major areas will
be seen to register the highest risk of ovarian cancer mor-
tality on mainland Spain. The first of these lies in Asturias
and the north of Corunna and Lugo (mainly in coastal
towns). The second is situated in Catalonia, specifically in
the eastern area of Lerida, northern Tarragona, Gerona
and Barcelona. In this last-mentioned province, there was
a noteworthy concentration of towns with elevated risks
in the Osona district. Finally, we detected a third high-risk
area formed by towns lying south-east of Huelva, west of
Seville and south of Cadiz. With regard to Spain's offshore
territories, a higher risk of mortality was observed on
Eivissa (Balearic Isles), El Hierro and northern Tenerife
(Canary Islands). The regions showing the lowest risk
associated with this tumour lay in eastern Andalusia,
western Murcia, Navarre, the west of Corunna and on the
Canary Islands (except for El Hierro and Tenerife).
On the map depicting the spatial pattern of the posterior
probability of RR being greater than 1 (Figure 4), towns
with a statistically significant excess risk (probabilities of
over 0.8) are shown in orange and red. Many of these
towns coincide with provincial capitals, e.g., Lugo,
Oviedo, Santander, León, Burgos, Bilbao, Pamplona, Val-
ladolid, Madrid, Zaragoza, Barcelona, Castellón, Valencia,
Huelva, Seville and Santa Cruz de Tenerife. However,
rural areas with significant excess risk were also detected,
such as the islands of Eivissa and El Hierro, the north of
Lugo, and inland areas of Barcelona and Gerona, with
attention again being drawn to the concentration of high-
est risk in the Osona district.
Municipal distribution of ovarian cancer mortality Figure 2
Municipal distribution of ovarian cancer mortality. Standardised mortality ratios (SMR). Spain, 1989–1998.
Ovarian Cancer ICD 183 1989−1998
      SMR      (towns)
       >=1.50   (1327)
1.30 − 1.50     (198)
1.10 − 1.30     (273)
1.05 − 1.10       (67)
0.95 − 1.05     (156)
0.91 − 0.95       (59)
0.77 − 0.91     (188)
0.67 − 0.77     (108)
        < 0.67   (5829)BMC Cancer 2008, 8:258 http://www.biomedcentral.com/1471-2407/8/258
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Shown in Table 1 is information on the most representa-
tive towns with excess ovarian cancer mortality. The selec-
tion criteria used were towns having: an RR of over 1.2; a
posterior probability that RR > 1 being greater or equal to
0.8; and a difference between observed and expected cases
of 3 or more. A total of 49 towns, belonging to 13 prov-
inces, met these criteria. Of these towns, 41% were situ-
ated in Catalonia, with Valverde, on the Island of El
Hierro, followed by Eivissa being the towns with the high-
est RRs in Spain.
Discussion
This study reveals some differences in the distribution of
ovarian cancer mortality at a small-area level in Spain. The
towns with highest risk are located in the north of Lugo
and Asturias, interior of Barcelona and Gerona, along the
Seville-Huelva boundary, and on the islands of Eivissa
and El Hierro. Although this pattern is, in general, in line
with a study previously undertaken at a provincial level
[17], analysis at a municipal level has enabled small areas
of higher risk that remained concealed at the provincial
scale, to be detected.
Standard errors of SMR are inversely dependent on the
number of expected cases. This implies that the most
extreme SMRs occur in small population areas and are
based on a small number of cases. Maps of unsmoothed
SMRs are therefore dominated by "green areas" (low RRs)
and "red areas" (high RRs), most likely reflecting random
variation. The smoothed map, however, tends to elimi-
nate part of this random variability, solely highlighting
those areas in which the risk is concentrated, so that a
town with no ovarian cancer deaths could be regarded as
having excess risk due to the elevated risk of its neigh-
bours and vice-versa. As a result, this could give rise to
false positives (enhancing the risk of some towns) or false
negatives (attenuating the risk of others).
When it comes to interpreting results, some factors must
be taken into account. Firstly, ovarian carcinoma is an
Municipal distribution of ovarian cancer mortality Figure 3
Municipal distribution of ovarian cancer mortality. Smoothed relative risk (RR) under the BYM model. Spain, 1989–1998.
Ovarian Cancer ICD 183 1989−1998
  Smoothed RR   (towns)
       >=1.50         (9)
1.30 − 1.50       (55)
1.10 − 1.30     (593)
1.05 − 1.10     (318)
0.95 − 1.05   (1723)
0.91 − 0.95   (1370)
0.77 − 0.91   (3533)
0.67 − 0.77     (468)
        < 0.67     (136)BMC Cancer 2008, 8:258 http://www.biomedcentral.com/1471-2407/8/258
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under-certified tumour in Spain, with a detection rate of
74% and confirmation rate of 81%, according to Percy's
criteria [26]. In fact, until the introduction of CIE-8 many
ovarian cancer deaths were erroneous certified [7]. Accu-
racy of ovary-neoplasm certification seems to vary widely
among studies. While some reported cases of death due to
ovarian cancer were really due to abdominal or uterine
neoplasms, in some studies, <<unspecified uterus
tumoursŬ would appear to include some ovarian cancers
as well as tumours of the cervix and endometrium [26]. If
this misclassification were not uniform throughout the
country, the spatial distribution of mortality due to this
tumour might be affected by this problem. However,
excess deaths due to ovarian cancer are concentrated in a
series of specific towns, whereas certification and coding
is uniform across municipalities in one autonomous
region. Another point to bear in mind are possible
regional differences in quality of medical care, reduced
access to it, differences in diagnostic and therapeutic tech-
niques, or even random variation, still present even using
smoothed estimates.
Geographical differences in the prevalence of some risk
factors documented for this tumour could have an influ-
ence on the spatial mortality pattern observed in this
study. One well-confirmed risk factor is family history.
Approximately 10% of epithelial ovarian tumours are
hereditary, with BRCA mutations being responsible for
the majority of cases [11,27,28]. The contribution of these
mutations varies among the populations depending on
their penetrance and prevalence, with the latter being pos-
sibly influenced by founder mutations. In Spain, a study
targeting BRCA1 and BRCA2 mutations in Spanish fami-
lies with breast/ovarian cancer highlighted a high propor-
tion of variations that appear to be unique to Spaniards,
and the existence of recurrent variations associated with
the geographical origin of the families [29]. In support of
this argument, mention should be made of the coinci-
dence between the ovarian cancer mortality pattern
detected in the south-west of the country and the breast
cancer mortality pattern detected in the same area among
premenopausal women [30], a group in which the hered-
itary component assumes major force.
Municipal distribution of ovarian cancer mortality Figure 4
Municipal distribution of ovarian cancer mortality. Posterior probability of RR being greater than 1. Spain, 1989–1998.
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Table 1: Selected towns and cities with excess ovarian cancer mortality.* Spain 1989–1998.
Autonomous Region Province/Island Municipality * Obs Exp SMR Smoothed RR P (RR > 1)
ANDALUSIA
Cadiz CHIPIONA 10 3.27 3.06 1.49 0.872
Huelva HINOJOS 5 1.14 4.39 1.26 0.822
Huelva HUELVA 57 41.76 1.37 1.24 0.926
Seville PILAS 10 3.25 3.08 1.39 0.892
Seville SANLUCAR LA MAYOR 8 2.75 2.91 1.28 0.847
ASTURIAS
Asturias AVILES 38 31.00 1.23 1.23 0.934
Asturias CASTRILLON 14 7.28 1.92 1.45 0.975
Asturias OVIEDO 104 78.66 1.32 1.28 0.994
Asturias PILOÑA 10 5.19 1.93 1.24 0.836
Asturias PRAVIA 8 4.84 1.65 1.34 0.913
Asturias SOTO DEL BARCO 6 2.12 2.84 1.48 0.941
Asturias TINEO 12 6.46 1.86 1.27 0.873
Asturias VILLAVICIOSA 13 7.91 1.64 1.27 0.867
BALEARIC ISLANDS
Balearic Islands ANDRAITX 6 2.82 2.13 1.39 0.839
Balearic Islands CALVIA 11 5.22 2.11 1.36 0.861
Balearic Islands EIVISSA 16 7.85 2.04 1.71 0.993
CANARY ISLANDS
Sta. Cruz de Tenerife CANDELARIA 8 3.12 2.56 1.28 0.846
Sta. Cruz de Tenerife LAGUNA (LA) 39 30.20 1.29 1.21 0.916
Sta. Cruz de Tenerife REALEJOS (LOS) 15 7.87 1.91 1.37 0.894
Sta. Cruz de Tenerife SANTA CRUZ DE TENERIFE 77 62.00 1.24 1.22 0.966
Sta. Cruz de Tenerife VALVERDE 5 1.48 3.38 2.16 0.927
CANTABRIA
Cantabria SANTA CRUZ DE BEZANA 6 1.85 3.25 1.32 0.818
CATALONIA
Barcelona BARBERA DEL VALLES 13 6.39 2.03 1.36 0.910
Barcelona IGUALADA 23 12.42 1.85 1.49 0.983
Barcelona MARTORELL 12 5.86 2.05 1.41 0.942
Barcelona MOLINS DE REI 12 6.29 1.91 1.28 0.890
Barcelona PRATS DE LLUÇANES 6 1.12 5.36 1.58 0.976
Barcelona PUIG-REIG 6 2.31 2.60 1.37 0.945
Barcelona SANT CELONI 10 4.17 2.40 1.30 0.863
Barcelona SANT MARTI SARROCA 4 0.99 4.06 1.24 0.826
Barcelona SANT PERE DE RIBES 12 4.23 2.84 1.48 0.930
Barcelona SANT PERE DE RIUDEBITLLES 4 0.83 4.85 1.39 0.895
Barcelona TORELLO 11 4.15 2.65 1.54 0.981
Barcelona VIC 22 11.76 1.87 1.51 0.993
Gerona AMER 4 1.00 4.00 1.36 0.901
Gerona CELRA 4 0.85 4.70 1.34 0.852
Gerona PUIGCERDA 7 2.28 3.07 1.53 0.912
Gerona SALT 11 6.71 1.64 1.31 0.898
Gerona SANT FELIU DE GUIXOLS 10 6.18 1.62 1.30 0.837
Gerona SARRIA DE TER 5 1.18 4.25 1.42 0.894
Gerona TORROELLA DE MONTGRI 6 2.49 2.41 1.29 0.821
Tarragona REUS 45 29.63 1.52 1.30 0.947
GALICIA
Corunna FERROL 44 34.78 1.27 1.24 0.925
Lugo CERVO 7 3.62 1.94 1.36 0.886
Lugo LUGO 51 33.02 1.55 1.30 0.945
Lugo MONDOÑEDO 7 3.37 2.08 1.24 0.846
Lugo VIVEIRO 12 6.39 1.88 1.42 0.941
VALENCIAN REGION
Valencia ALDAIA 12 6.23 1.93 1.26 0.824
Valencia TORRENT 29 17.13 1.69 1.29 0.897
Obs = observed deaths; Exp = expected deaths; SMR = standard mortality ratio; Smoothed RR = smoothed relative risk; P (RR > 1) = posterior 
probability that RR > 1.
* Municipalities that fulfil the following criteria: RR > = 1.2; (P(RR) > 1) > = 0.8 and (Obs – Exp) > = 3BMC Cancer 2008, 8:258 http://www.biomedcentral.com/1471-2407/8/258
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Ovarian cancer mortality in Spain described a strongly ris-
ing trend in the 20th century. An important factor in the
analysis of the components of this trend is a strong and
sustained increase in birth-cohort-related risk from the
beginning of the series until the 1930s [6,7,31]. This effect
reflects an important change in the lifestyle of Spanish
women, determined in great measure by socio-cultural
changes, the incorporation of women into the job market,
longer educational periods, improvements in the quality
of life and swift urbanisation. These events have led to
modification of certain hormonal and reproductive fac-
tors, both positively and negatively associated with ovar-
ian cancer, such as fertility, use of oral contraceptives,
tubal ligation and replacement hormone therapy. We
have not sufficiently detailed information to confirm if
geographical differences in the prevalence of some of
these risk factors have an influence in the mortality pat-
tern observed. Nevertheless, some of these changes (e.g.,
fall in the birth rate, a rise in the age at which women have
their first child or reduced breastfeeding) have occurred
earlier in urban areas and might have contributed to the
increase in mortality observed in many provincial capi-
tals. In this respect, regions in the north of Spain have reg-
istered the highest delay of the age of first birth and the
lowest fecundity nationwide. Among these, mention
should be made of Asturias as the region with fewest chil-
dren per woman during the preceding 30 years [32,33].
The concentration of higher ovarian cancer mortality in
narrowly localised geographical areas, leads one to con-
sider the possible influence of exposure to certain envi-
ronmental pollutants or occupational exposures. Many
municipalities with high excess risk are localised in the
province of Barcelona and the town of Pilas in Seville
Province, where the economic activity has traditionally
been based on textiles, and it is being currently hit very
hard by the crisis in the sector. There are a number of
papers in the literature that have found an association
between this tumour and the textile or leather industries
[34-40], and in practically all cases this association was
related with exposure to asbestos fibres [34-36,38]. This
type of industry uses chrysotile during the fabric-making
operations of carding, spinning, weaving, dyeing and fin-
ishing, as well as machinery maintenance [41]. In the
early 20th century, mechanisation of the process in the
Catalonian textile industry was accompanied by the sub-
stitution of women for men [42]. One argument that
would support this hypothesis is the fact that pleural can-
cer mortality is also very high in the same areas of the
province of Barcelona [43].
Furthermore, unirrigated crop farming and animal hus-
bandry-basically pig farming- are both activities that have
been strongly rooted in this area. One of the major prob-
lems confronting this region, and the Osona district in
particular, is the nitrate pollution of aquifers as a conse-
quence of the excessive dumping of purines. Many towns
in these districts have been declared "vulnerable zones to
pollution by nitrates from agricultural sources" [44,45],
and the drinking water supplied to inhabitants of these
municipalities was found to have a nitrate content exceed-
ing legally stipulated levels [46]. In fact, the disputes gen-
erated in areas such as Baix Ter and Osona have been
formally brought before the European Commission and,
ultimately, the Court of Justice of the European Commu-
nities [46]. The Guadalquivir basin has also been affected
by contamination of its groundwaters. Twenty five percent
of its aquifers register nitrate levels in excess of those per-
mitted by law [47]. Although there is no clear evidence of
an association between exposure to nitrates and risk of
ovarian cancer, a positive association has indeed been
detected with consumption of polluted water in a cohort
of Iowa women, with the risk rising in response to
increases in the nitrate content of the drinking water [48].
Conclusion
In brief, the geographical study of municipal ovarian can-
cer mortality shows a marked excess risk in certain towns
in the north of Asturias and Lugo, inland areas of Barce-
lona and Gerona, along the Seville-Huelva boundary, and
on the Islands of Eivissa and El Hierro. Even though well
established ovarian cancer risk factors do not seem to con-
tribute significantly to the spatial distribution of ovarian
cancer mortality, hormonal and reproductive changes that
occurred in women's lifestyle earlier in urban areas might
have contributed to the increase in mortality observed in
many provincial capitals. Likewise, regional variations in
medical care; and different diagnostic and therapeutic
techniques could have played a role. Finally, environmen-
tal or occupational exposures to certain carcinogenic
agents might also have influenced on the more localised
excess mortality areas. Nevertheless, the descriptive nature
of this study and the limited knowledge of ovarian cancer
pathogenesis make it difficult to draw any conclusions on
the real determinants implicated in the mortality pattern
observed.
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